This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch
by Zacks Equity Research
BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.
Hologic (HOLX) ThinPrep Genesis Processor Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.
BD's (BDX) First Self-Collection HPV Screening Assay Gets CE Mark
by Zacks Equity Research
BD's (BDX) industry-first CE marked self-collection claim for HPV screening enables greater access to testing for women.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.
National Vision (EYE) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
National Vision's (EYE) transitions of five additional Walmart Vision Centers in 2020, which have become operative of late, are expected to post positive Q1 results.
GoodRx (GDRX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
GoodRx' (GDRX) manufacturer solutions offerings continue to grow at a strong rate, registering record bookings over the past months.
Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 4.93% and 1.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Becton, Dickinson (BDX)
by Zacks Equity Research
Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in Pharmaceutical segment.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect weak segmental performance.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) second-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19
by Sriparna Ghosal
Let's take a look at the three women healthcare MedTech stocks performing well lately.
3 GARP MedTech Stocks to Snap Up Despite Pandemic Woes
by Trina Mukherjee
Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.
BD's (BDX) $65M Investment to Boost Supply-Chain Strength
by Zacks Equity Research
BD's (BDX) $65-million investment in constructing an advanced facility will become integral to the U.S. medical device supply chain.
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Hill-Rom Holdings, Owens & Minor, McKesson Corp and Meridian Bioscience
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Hill-Rom Holdings, Owens & Minor, McKesson Corp and Meridian Bioscience
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
by Urmimala Biswas
We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.
4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic
by Trina Mukherjee
Grab these four top stocks, HRC, OMI, MCK and VIVO, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
by Zacks Equity Research
BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
The Zacks Analyst Blog Highlights: NVIDIA, Accenture, Goldman Sachs, Becton, Dickinson and Co and Southern Copper
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Accenture, Goldman Sachs, Becton, Dickinson and Co and Southern Copper
Top Research Reports for NVIDIA, Accenture & Goldman Sachs
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including NVIDIA (NVDA), Accenture (ACN), and Goldman Sachs (GS).
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
BD (BDX), ImageMover Partner for Rapid Antigen Test Reporting
by Zacks Equity Research
BD (BDX) collaborates with ImageMover to streamline rapid antigen testing results performed on the BD Veritor Plus System.
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.